Stock ANIP ANI PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights ANI Pharmaceuticals, Inc.

Equities

ANIP

US00182C1036

Market Closed - Nasdaq
Other stock markets
 21:00:00 07/05/2024 BST 		5-day change 1st Jan Change
66.72 USD -0.95% Intraday chart for ANI Pharmaceuticals, Inc. +1.09% +21.00%
05-03 Ani Pharmaceuticals Insider Sold Shares Worth $1,332,400, According to a Recent SEC Filing MT
04-17 Ani Pharmaceuticals Insider Sold Shares Worth $1,500,589, According to a Recent SEC Filing MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension
CI
ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP
CI
ANI Pharmaceuticals Shares Rise After Q4 Adjusted Earnings, Net Revenue Beat Forecasts
MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024
CI
(ANIP) ANI PHARMACEUTICALS Sees Fiscal Year 2024 Revenue Range $520M - $542M
MT
(ANIP) ANI PHARMACEUTICALS Expects Fiscal Year 2024 EPS Range $4.26 - $4.67
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Posts Q4 Revenue $131.7M, vs. Street Est of $124.9M
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q4 EPS $1.00, vs. Street Est of $0.86
MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
ANI Pharmaceuticals Launches Pentoxifylline Extended-Release Tablets
MT
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP
CI
ANI Pharmaceuticals Receives US FDA Approval for Indomethacin Oral Suspension
MT
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP
CI
Lupin Gets US FDA Nod for Hypertension Treatment Drug
MT
ANI Pharmaceuticals Shares Fall Despite Higher Q3 Results, Raised 2023 Guidance
MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
(ANIP) ANI PHARMACEUTICALS Sees Fiscal Year 2023 EPS Range $4.29 - $4.57
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q3 Revenue $131.8M
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Posts Q3 EPS $1.27
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANIP Stock
  4. News ANI Pharmaceuticals, Inc.
  5. Highlights